Aileron Therapeutics (ALRN) Gets a Buy Rating from JonesTrading

JonesTrading analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics (ALRNResearch Report) today and set a price target of $5.00. The company’s shares closed last Tuesday at $1.58.

According to, Roy is a top 100 analyst with an average return of 65.1% and a 58.2% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Monopar Therapeutics Inc.

Aileron Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $3.50, representing an 110.8% upside. In a report issued on February 16, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.47 and a one-year low of $0.25. Currently, Aileron Therapeutics has an average volume of 4.21M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.